Associations between receipt of prescribed safer supply and health and social outcomes in the short term: a prospective cohort study

BACKGROUND: British Columbia, Canada introduced clinical guidance to support the prescription of pharmaceutical alternatives to the toxic unregulated drug supply in 2020, also known as prescribed safer supply (PSS). This provincial prospective cohort study evaluates the associations between PSS receipt and self-reported health and social outcomes. METHODS: Data were collected in 2020-2021 using a longitudinal survey of people who had received a prescription or were seeking one (n = 161), with up to 5 time points per participant over 3 months. Generalised estimating equations were used to assess the effects of time-varying prescription exposure (yes/no) on outcomes over the follow-up period, controlling for encounters with police and bylaw officers, service use, social support, and sociodemographic characteristics. Outcomes included quality of life (EuroQOL-5D), depression (PHQ-2), anxiety (GAD-2), frequency of unregulated substance use, COVID-19 protective behaviours, and reliance on criminalized income sources. RESULTS: PSS receipt was negatively associated with depression (adj. b = -0.44, 95% CI= -0.81, -0.08) and frequency of unregulated substance use (adj. b = -0.23, 95% CI = -0.45, -0.014) over the study period. Independent of PSS receipt, there was no evidence of change in outcomes over the 12 weeks, except for a small increase in COVID-19 protective behaviours over time (adj. b = 0.004, 95% CI = 0.001, 0.007). DISCUSSION: Findings signal the potential promise of PSS, along with the need for improvement of existing service models. Further research is needed to inform the development of models that combine prescriptions with comprehensive services and supports to maximize positive outcomes.

Authors

Institutions

Publication Details

Journal
International Journal of Drug Policy
Published
2026-11-18
DOI
https://doi.org/10.1016/j.drugpo.2026.105605
Primary Topic
HIV, Drug Use, Sexual Risk
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Associations between receipt of prescribed safer supply and health and social outcomes in the short term: a prospective cohort study

Brittany Barker, Bernie Pauly, Amanda Slaunwhite, Karen A. Urbanoski et al.
3 links
International Journal of Drug Policy
HIV, Drug Use, Sexual Risk
article

Associations between receipt of prescribed safer supply and health and social outcomes in the short term: a prospective cohort study

Brittany Barker, Bernie Pauly, Amanda Slaunwhite, Karen A. Urbanoski, Thea van Roode, Bohdan Nosyk, Omid Gheysar Gharamaleki, Katherine Hogan
article en

Abstract

BACKGROUND: British Columbia, Canada introduced clinical guidance to support the prescription of pharmaceutical alternatives to the toxic unregulated drug supply in 2020, also known as prescribed safer supply (PSS). This provincial prospective cohort study evaluates the associations between PSS receipt and self-reported health and social outcomes. METHODS: Data were collected in 2020-2021 using a longitudinal survey of people who had received a prescription or were seeking one (n = 161), with up to 5 time points per participant over 3 months. Generalised estimating equations were used to assess the effects of time-varying prescription exposure (yes/no) on outcomes over the follow-up period, controlling for encounters with police and bylaw officers, service use, social support, and sociodemographic characteristics. Outcomes included quality of life (EuroQOL-5D), depression (PHQ-2), anxiety (GAD-2), frequency of unregulated substance use, COVID-19 protective behaviours, and reliance on criminalized income sources. RESULTS: PSS receipt was negatively associated with depression (adj. b = -0.44, 95% CI= -0.81, -0.08) and frequency of unregulated substance use (adj. b = -0.23, 95% CI = -0.45, -0.014) over the study period. Independent of PSS receipt, there was no evidence of change in outcomes over the 12 weeks, except for a small increase in COVID-19 protective behaviours over time (adj. b = 0.004, 95% CI = 0.001, 0.007). DISCUSSION: Findings signal the potential promise of PSS, along with the need for improvement of existing service models. Further research is needed to inform the development of models that combine prescriptions with comprehensive services and supports to maximize positive outcomes.

International Journal of Drug PolicyVol. 159
University of British Columbia (CA), Simon Fraser University (CA), University of Victoria (CA), St. Paul's Hospital (CA), BC Centre for Disease Control (CA), Centre for Advancing Health Outcomes (CA), First Nations Health and Social Secretariat of Manitoba (CA), Canadian Institute for Substance Use Research (CA), First Nations Health Authority (CA)
Michael Smith Health Research BC, Ministry of Health, British Columbia, Victoria General Hospital Foundation, Canadian Institutes of Health Research
Good health and well-being
HIV, Drug Use, Sexual Risk
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon